Health and Medical Information » Cancer

SUTENT(R) Cost Effective Advantage Predicted In Treating Patients With Metastatic Renal Cell Carcinoma

admin — Mon, 15 Sep 2008 21:50:02 +0000

Results from an international study presented today at the European Society for Medical Oncology (ESMO) predict that sunitinib (SUTENTÂ®) is cost effective as a first-line therapy for patients with metastatic renal cell carcinoma (mRCC).

Share and Enjoy: These icons link to social bookmarking sites where readers can share and discover new web pages.

Merck KGaA: Erbitux - First Treatment In 30 Years To Prolong Survival In 1st-Line Recurrent And/Or Metastatic Head And Neck Cancer

admin — Mon, 15 Sep 2008 21:49:58 +0000

Data presented at the 33rd European Society for Medical Oncology (ESMO) Congress in Stockholm demonstrate that the addition of ErbituxÂ® (cetuximab) to platinum-based chemotherapy increases overall survival (OS) compared to chemotherapy alone in the 1st-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN).

Share and Enjoy: These icons link to social bookmarking sites where readers can share and discover new web pages.

Appropriate Lifestyle Choices Can Reduce The Risk Of Breast Cancer - Europa Donna

admin — Mon, 15 Sep 2008 21:49:57 +0000

Breast cancer claims the lives of more European women than any other cancer. Almost 132,000 women died from breast cancer in 2006, and every year 430,000 European women are diagnosed with the disease.1 But studies show that having a healthy lifestyle - avoiding weight gain, eating nutritiously and being physically active - can greatly reduce a woman’s risk of developing breast cancer. As much as 25-33% of breast cancer cases are related to being overweight and physically inactive.

Share and Enjoy: These icons link to social bookmarking sites where readers can share and discover new web pages.

Breast-Conserving Surgery More Likely At Breast Centers

admin — Mon, 15 Sep 2008 21:49:55 +0000

Breast cancer patients are twice as likely to be offered breast-conserving surgery if treated by surgeons at breast centers than by surgeons in private practice, according to a national survey of breast specialists conducted by the American Society of Breast Disease. The survey presented a case study of a woman from her initial workup following a mammogram through diagnosis to surgical treatment.

Share and Enjoy: These icons link to social bookmarking sites where readers can share and discover new web pages.

Promising Clinical Phase I Results For Intravenous CP-4126 For Patients With Solid Tumours

admin — Mon, 15 Sep 2008 21:49:54 +0000

Clavis Pharma ASA (OSE: CLAVIS) announced that promising results from its Intravenous CP-4126 Phase I study in patients with solid tumours have been presented at the European Society for Medical Oncology (ESMO) Meeting 2008. The presentation was held on 13 September. Intravenous CP-4126 is a novel anticancer agent designed to circumvent important drug resistance mechanisms.

Share and Enjoy: These icons link to social bookmarking sites where readers can share and discover new web pages.

Renal Cell Carcinoma Rates Compared With Health Status And Behavior In The United States

admin — Mon, 15 Sep 2008 21:49:51 +0000

UroToday.com - Renal cell cancer is the third most common urologic malignancy and the seventh most common cancer overall. Incidence rates have been increasing steadily each year in the United States (U.S.) and Europe during the last 3 decades1. There are projected to be 54,390 new cases and 13,010 deaths from renal cell cancer in 2008 in this country2. Renal cell cancer imposes a significant burden on the U.S.

Share and Enjoy: These icons link to social bookmarking sites where readers can share and discover new web pages.

HER2 Breast Cancer Vaccine Shows Promise In Lab

admin — Mon, 15 Sep 2008 21:49:49 +0000

Researchers in the US are hoping that their new breast cancer vaccine will be effective in humans because it safely destroyed HER2-positive tumors, even those resistant to anti-HER2 drugs, when tested on mice. The study was the work of scientists at the School of Medicine and Karmanos Cancer Institute, Wayne State University, Detroit, Michigan, and is published in the September 15 issue of Cancer Research, a journal of the American Association for Cancer Research.

Share and Enjoy: These icons link to social bookmarking sites where readers can share and discover new web pages.

Avastin(R)(bevacizumab) Continues To Demonstrate Long Term Survival For Patients With Metastatic Colorectal Cancer

admin — Mon, 15 Sep 2008 21:49:48 +0000

Avastin’s (bevacizumab) role in the treatment of patients with metastatic colorectal cancer (mCRC), the world’s second most common cancer, was strengthened at the 33rd European Society of Medical Oncology (ESMO) meeting with a compelling data set including: - the final overall sur

Share and Enjoy: These icons link to social bookmarking sites where readers can share and discover new web pages.

New Tool To Speed Cancer Therapy Approval Available

admin — Mon, 15 Sep 2008 21:49:46 +0000

Although cancer remains a leading cause of death in America, it can take up to 12 years to bring a new anti-cancer agent before the FDA and the success rate for approval is only five to 10 percent. That means many research hours and dollars are wasted chasing avenues that will not bring fruit. The National Cancer Institute’s Translational Research Working Group (TRWG) developed a set of tools that it believes will improve that process.

Share and Enjoy: These icons link to social bookmarking sites where readers can share and discover new web pages.

California Researcher And Surgeon, Donald L. Morton, MD, To Receive ACCC’s Clinical Research Award

admin — Mon, 15 Sep 2008 21:49:44 +0000

Donald L. Morton, MD, will receive the Association of Community Cancer Centers’ 2008 Clinical Research Award. He will be honored for his extensive research, leadership, and commitment to individuals with melanoma. Dr. Morton is chief of the Melanoma Program and director of the Surgical Oncology Fellowship Program at the John Wayne Cancer Institute at Saint John’s Health Center in Santa Monica, Calif. Dr.

Share and Enjoy: These icons link to social bookmarking sites where readers can share and discover new web pages.